GSK licenses HUTCHMED’s solid tumour conjugate in up to $1.3bn deal
GSK will pay a subsidiary of HUTCHMED $110m upfront for a novel type of drug designed to selectively target solid…
03 Sep 2026
Typewriter raises $56m Series A to progress non-viral gene therapy platform
Biotech startup Typewriter Therapeutics has emerged from stealth with $56m in capital as it looks to progress its non-viral in vivo gene therapy platform closer to the clinic. The Series…
03 Sep 2026
Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule
China-based Biocytogen Pharmaceuticals has entered a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human VHH antibody molecule. The contract allows Qilu Pharmaceutical to use the antibody, which was…
03 Sep 2026
Novartis signs $3.2bn drug delivery deal with Alteogen
Novartis has signed an agreement with Alteogen that could be worth up to $3.22bn for the development and commercialisation of subcutaneous drug formulations using Alteogen’s ALT-B4 technology. The deal allows…
02 Sep 2026
FDA cracks down on online black market for weight loss peptides
The US Food and Drug Administration (FDA) has continued its clampdown on the illegal trade of black-market peptides by issuing a string of warnings to online sellers, as non-approved drugs…
02 Sep 2026
Roche licenses Simcere’s B-cell-targeting tri-specific for $1.53bn
Roche is outlaying $1.53bn for the global rights to Simcere Zaiming’s trispecific antibody targeting B-cell-mediated diseases, marking the second time in a month that the Swiss pharma company has ventured…
02 Sep 2026
Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology
Japan-based Ono Pharmaceutical has signed an agreement with US biotechnology company Aitia to collaborate on drug discovery in neurological diseases. The agreement will see Aitia apply its REFS technology to…